Obstructive hypertrophic cardiomyopathy: a review of new therapies.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2023-10-01 Epub Date: 2023-11-07 DOI:10.2217/fca-2023-0056

Nandini Mehra, Adel Hajj Ali, Milind Y Desai

引用次数: 0

Abstract

Hypertrophic cardiomyopathy (HCM) is a phenotypically heterogeneous disease with a genetic basis and variable penetrance. The hallmarks of HCM include dynamic left ventricular outflow tract obstruction, typically caused by asymmetric septal hypertrophy. However, abnormal papillary muscle placement, abnormal mitral valve and subvalvular apparatus and apical hypertrophic forms have also been described. Typical medical treatment has been stagnant for decades, although there have been significant advances in surgical treatment of patients with obstructive HCM. Herein, we describe a new class of drugs targeting the specific pathophysiology of HCM.

查看原文本刊更多论文

梗阻性肥厚型心肌病：新疗法综述。

肥厚型心肌病（HCM）是一种表型异质性疾病，具有遗传基础和变异外显率。HCM的特征包括动态左心室流出道梗阻，通常由不对称间隔肥大引起。然而，乳头肌位置异常、二尖瓣和瓣下器异常以及心尖肥大也有描述。尽管阻塞性HCM患者的外科治疗取得了重大进展，但典型的医疗治疗几十年来一直停滞不前。在此，我们描述了一类针对HCM特定病理生理学的新药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.